Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Frank E.H.P. van Baarle et al.|The Lancet Rheumatology|2020Cited by 199
Regulatory role of C5a in LPS‐induced IL‐6 production by neutrophils during sepsisNiels C. Riedemann, Peter A. Ward|The FASEB Journal|2003Cited by 180
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143
Distinct Different Contributions of the Alternative and Classical Complement Activation Pathway for the Innate Host Response during SepsisKatja Dahlke, Niels C. Riedemann|The Journal of Immunology|2011Cited by 37
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)Michael Bauer, A. Weyland, Gernot Marx et al.|Critical Care Explorations|2021Cited by 36